抄録
In a clinical trial of the efficacy of roxithromycin (RXM) 150mg was administered twice a day to patients with chronic sinusitis. Subjective improvement was noted in 72.4%, and objective improvement was confirmed in 65.5% by endonasal findings and in 44.8% by X-ray findings after treatment with RXM for 8 to 12 weeks. One patient complained of epigastric pain, but it was mild. The administration of RXM did not affect the nasal bacterial flora.
An in vitro study showed that RXM significantly suppressed the production of TNF-a by tonsillar cells stimulated with PHA, LPS or RSV. RXM also blocked the disturbance of ciliary activity in nasal epithelial cells induced by the administration of TNF-a. RXM may control inflammation by suppressing the production of and blocking the adverse effects of certain regulatory cytokines.
